by Dr. Joseph Mercola

As the U.S., U.K. and other countries around the world prepare for a fall vaccination campaign against both the flu and covid, it’s worth taking note of some basic facts. In “Untested Bivalent COVID Jab Being Rolled Out,” I reviewed potential problems with Moderna’s new bivalent covid shot for adults, authorized by the U.K. in mid-August 2022.

August 23, 2022, Pfizer and Moderna submitted their respective authorization requests to the U.S. Food and Drug Administration.1 Pfizer is releasing a bivalent injection targeting Omicron subvariants BA.4 and BA.5, which are the two currently in circulation, while Moderna’s shot targets the already extinct Wuhan strain and Omicron subvariant BA.1.2

August 31, the FDA authorized both.3 The bivalent boosters will only be available to those who have already received the primary two-dose series and/or a monovalent booster at least two months ago. Per the FDA:4

“The Moderna covid-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 18 years of age and older. The Pfizer-BioNTech covid-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 12 years of age and older …

With today’s authorization, the monovalent mRNA covid-19 vaccines are not authorized as booster doses for individuals 12 years of age and older … These monovalent vaccines continue to be authorized for use for administration of a primary series for individuals 6 months of age and older …

Individuals 18 years of age and older are eligible for a single booster dose of the Moderna covid-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent covid-19 vaccine. 

Individuals 12 years of age and older are eligible for a single booster dose of the Pfizer-BioNTech covid-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent covid-19 vaccine.”

The reformulated boosters will be available as soon as the U.S. Centers for Disease Control and Prevention gives its OK.5,6 For the record, all boosters, including these, are still under emergency use authorization (EUA) only, so manufacturers have no liability for injuries, and the reformulated shots are being released based on antibody levels in mice alone.

Read the rest